

# Deep Gray Matter Volume Loss Drives Disability Worsening in Multiple Sclerosis

Arman Eshaghi, MD <sup>1,2</sup> Ferran Prados, PhD,<sup>1,2,3,4</sup>

Wallace J. Brownlee, PhD, FRACP,<sup>1</sup> Daniel R. Altmann, PhD,<sup>1,5</sup>

Carmen Tur, MD, PhD,<sup>1</sup> M. Jorge Cardoso, PhD,<sup>2,3</sup> Floriana De Angelis, MD,<sup>1</sup>

Steven H. van de Pavert, PhD,<sup>1</sup> Niamh Cawley, MD, PhD,<sup>1</sup>

Nicola De Stefano, MD, PhD <sup>6</sup> M. Laura Stromillo, MD, PhD,<sup>6</sup>

Marco Battaglini, PhD <sup>6</sup> Serena Ruggieri, MD,<sup>7,8</sup> Claudio Gasperini, MD,<sup>7</sup>

Massimo Filippi, MD, FEAN,<sup>9</sup> Maria A. Rocca, MD,<sup>9</sup> Alex Rovira, MD,<sup>10</sup>

Jaume Sastre-Garriga, MD, PhD,<sup>11</sup> Hugo Vrenken, PhD,<sup>12</sup> Cyra E. Leurs, MD,<sup>13</sup>

Joep Killestein, MD, PhD,<sup>13</sup> Lukas Pirpamer, MSc,<sup>14</sup> Christian Enzinger, MD,<sup>14,15</sup>

Sebastien Ourselin, PhD,<sup>2,3,4</sup> Claudia A.M. Gandini Wheeler-Kingshott, PhD,<sup>1,16,17</sup>

Declan Chard, MD, PhD,<sup>1,4</sup> Alan J. Thompson, FMedSci,<sup>1</sup>

Daniel C. Alexander, PhD <sup>2</sup> Frederik Barkhof, MD, PhD,<sup>1,2,3,4,12</sup> and

Olga Ciccarelli, PhD, FRCP,<sup>1,4</sup> on behalf of the MAGNIMS study group\*

**Objective:** Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS.

**Methods:** We analyzed 3,604 brain high-resolution T1-weighted magnetic resonance imaging scans from 1,417 participants: 1,214 MS patients (253 clinically isolated syndrome [CIS], 708 relapsing-remitting [RRMS], 128 secondary-progressive [SPMS], and 125 primary-progressive [PPMS]), over an average follow-up of 2.41 years (standard deviation [SD] = 1.97), and 203 healthy controls (HCs; average follow-up = 1.83 year; SD = 1.77), attending seven European centers. Disability was assessed with the Expanded Disability Status Scale (EDSS). We obtained volumes of the

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com). DOI: 10.1002/ana.25145

Received Mar 10, 2017, and in revised form Oct 9, 2017. Accepted for publication Oct 10, 2017.

Address correspondence to Dr Arman Eshaghi, Queen Square Multiple Sclerosis Centre, Russell Square House, 10-12 Russell Square, London WC1B5EH, United Kingdom. E-mail: [arman.eshaghi.14@ucl.ac.uk](mailto:arman.eshaghi.14@ucl.ac.uk)

From the <sup>1</sup>Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London; <sup>2</sup>Centre for Medical Image Computing (CMIC), Department of Computer Science, University College London, London, United Kingdom; <sup>3</sup>Translational Imaging Group, Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, United Kingdom; <sup>4</sup>National Institute for Health Research (NIHR), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), London, United Kingdom; <sup>5</sup>Medical Statistics Department, London School of Hygiene & Tropical Medicine, London, United Kingdom; <sup>6</sup>Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy; <sup>7</sup>Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy; <sup>8</sup>Department of Neurology and Psychiatry, University of Rome Sapienza, Rome, Italy; <sup>9</sup>Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; <sup>10</sup>MR Unit and Section of Neuroradiology, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; <sup>11</sup>Department of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; <sup>12</sup>Department of Radiology and Nuclear Medicine, VU University Medical Centre, Amsterdam, The Netherlands; <sup>13</sup>Department of Neurology, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands; <sup>14</sup>Department of Neurology, Medical University of Graz, Graz, Austria; <sup>15</sup>Division of Neuroradiology, Vascular & Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria; <sup>16</sup>Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; and <sup>17</sup>Brain MRI 3T Mondino Research Center, C. Mondino National Neurological Institute, Pavia, Italy

\*MAGNIMS steering committee members are listed in the appendix of this article.

Additional supporting information can be found in the online version of this article.

deep GM (DGM), temporal, frontal, parietal, occipital and cerebellar GM, brainstem, and cerebral white matter. Hierarchical mixed models assessed annual percentage rate of regional tissue loss and identified regional volumes associated with time-to-EDSS progression.

**Results:** SPMS showed the lowest baseline volumes of cortical GM and DGM. Of all baseline regional volumes, only that of the DGM predicted time-to-EDSS progression (hazard ratio = 0.73; 95% confidence interval, 0.65, 0.82;  $p < 0.001$ ): for every standard deviation decrease in baseline DGM volume, the risk of presenting a shorter time to EDSS worsening during follow-up increased by 27%. Of all longitudinal measures, DGM showed the fastest annual rate of atrophy, which was faster in SPMS (−1.45%), PPMS (−1.66%), and RRMS (−1.34%) than CIS (−0.88%) and HCs (−0.94%;  $p < 0.01$ ). The rate of temporal GM atrophy in SPMS (−1.21%) was significantly faster than RRMS (−0.76%), CIS (−0.75%), and HCs (−0.51%). Similarly, the rate of parietal GM atrophy in SPMS (−1.24%) was faster than CIS (−0.63%) and HCs (−0.23%; all  $p$  values  $< 0.05$ ). Only the atrophy rate in DGM in patients was significantly associated with disability accumulation (beta = 0.04;  $p < 0.001$ ).

**Interpretation:** This large, multicenter and longitudinal study shows that DGM volume loss drives disability accumulation in MS, and that temporal cortical GM shows accelerated atrophy in SPMS than RRMS. The difference in regional GM atrophy development between phenotypes needs to be taken into account when evaluating treatment effect of therapeutic interventions.

ANN NEUROL 2018;00:000–000

The clinical course of multiple sclerosis (MS) is heterogeneous. Some patients experience relapses with recovery (relapsing-remitting [RR] MS), whereas others develop progressive disability either from the onset (primary-progressive [PP] MS), or after a period of relapses (secondary-progressive [SP] MS). RRMS patients account for approximately 90% of cases at onset,<sup>1</sup> whose majority later progress to SPMS. The pathogenic mechanisms driving accrual of disability are beginning to be elucidated<sup>2</sup>: Neurodegeneration plays a crucial role in determining accrual of disability over time.<sup>3</sup>

Neurodegeneration is reflected in vivo by reduced brain volume (or brain atrophy), which can be measured by magnetic resonance imaging (MRI).<sup>3</sup> Over time, brain volume declines more rapidly in MS patients when compared to age-matched healthy controls (HCs).<sup>3–6</sup> Across MS phenotypes, SPMS shows the fastest annual rate of brain atrophy, which is estimated to be 0.6% (compared to around 0.2% in age-matched HCs).<sup>5</sup> The role of brain atrophy in monitoring response to treatments in MS is evolving: Whole brain atrophy has been recently used as a primary outcome measure in phase II clinical trials in SPMS.<sup>7,8</sup>

Whole brain atrophy is mainly driven by neuroaxonal loss in the gray matter (GM).<sup>3</sup> GM volume loss is associated with long-term disability<sup>9,10</sup> and explains physical disability better than white matter<sup>9,11</sup> and whole brain atrophy.<sup>5</sup> Some GM regions, such as the cingulate cortex and thalamus, are affected by volume loss more extensively than others,<sup>12,13</sup> and the extent of their volume loss correlates with disability<sup>13,14</sup> and cognitive impairment.<sup>15</sup> Regional predilection for atrophy is not unique to MS; for example, hippocampal atrophy is more pronounced than the whole brain atrophy in the early phase of Alzheimer's disease (AD).<sup>16</sup> Although cross-sectional studies have previously shown patterns of

regional atrophy in different types of MS,<sup>12,17</sup> studies on longitudinal evolution of atrophy in different structures across MS phenotypes are scarce.


The overarching goal of our study was to investigate whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS. In a large, multicenter cohort, which included all MS phenotypes and HCs, we tested the following hypotheses: (1) Some GM regions show faster atrophy rate than others and their rate may differ between MS phenotypes; (2) smaller baseline volumes of brain structures, reflecting a more extensive neurodegeneration, predict disability accrual; and (3) the rate of regional volume loss is associated with the rate of disability accumulation.

## Patients and Methods

### Participants

In this retrospective study, we collected data from seven European MS centers (MAGNIMS: [www.magnims.eu](http://www.magnims.eu)) from 1,424 participants who have been studied between 1996 and 2016; we included participants who fulfilled the following criteria: (1) a diagnosis of MS according to 2010 McDonald Criteria<sup>18</sup> or a clinically isolated syndrome (CIS)<sup>19</sup>; (2) HCs without history of neurological or psychiatric disorders; (3) at least two MRI scans acquired with a minimal interval of 6 months with identical protocol, including high-resolution T1-weighted MRI (allowing regional gray and white matter segmentation), and T2/fluid-attenuated inversion recovery (FLAIR), sequences. Patients were scored on the Expanded Disability Status Scale (EDSS).<sup>20</sup> To increase the number of HCs scans, which were provided by four centers, we collected data from age-matched HCs from the Parkinson's Progression Marker's Initiative (PPMI; <http://www.ppmi-info.org/data>).

MRI scans were taken under consent obtained from each subject independently in each center. The final protocol for this study was reviewed and approved by the European MAGNIMS collaboration for analysis of pseudo-anonymized scans.



**FIGURE 1: Image analysis pipeline.** An unbiased symmetric image registration approach was used to calculate atrophy. [Color figure can be viewed at [www.annalsofneurology.org](http://www.annalsofneurology.org)]

### Image Acquisition

We included scans from 13 different MRI protocols; all centers except one provided three-dimensional (3D)/T1-weighted scans (Supplementary Tables 1 and 2 show the MRI protocols).

### Image Analysis

We performed image analysis as follows.

**BIAS FIELD CORRECTION.** We used N4 bias field correction to correct for field inhomogeneity in T1-weighted scans using ANTs v2.10.<sup>21</sup>

**LESION FILLING.** Lesion masks were manually delineated on PD/T2 images by different raters at each center semiautomatically, except for three centers that used the same automatic lesion segmentation with LST toolbox (version 2.0.15).<sup>22</sup> We calculated linear transformation matrices to register T2/FLAIR with the T1-weighted scan using FSL-FLIRT v5.0.<sup>23</sup> Then, we applied these matrices to lesion masks to transfer them into the accompanying T1 subject space. We used the FSL lesion filling method, which uses a white matter mask calculated with FSL-FAST<sup>24</sup> to fill T1 hypointensities within normal-appearing whiter matter, so as to reduce segmentation errors, as previously done.<sup>25–27</sup>

**SYMMETRIC WITHIN-SUBJECT REGISTRATION.** To avoid asymmetric registration and interpolation of longitudinal scans (eg, toward the baseline scan), we constructed an unbiased subject-specific template that has “equal distance” from each time point using FreeSurfer version 5.3.<sup>28–30</sup> We linearly transformed T1-weighted images to this symmetric space with the unbiased transformation matrix for each time point and used cubic B-spline interpolation to reduce interpolation artefacts. We manually checked the alignment of scans in the symmetric space.

**TISSUE SEGMENTATION.** Next, in the symmetric space, we segmented T1 scans into the GM, white matter, and cerebrospinal fluid (CSF) with the Geodesic Information Flow (GIF) software (part of NiftySeg: <http://cmictig.cs.ucl.ac.uk/niftyweb/program.php?p=GIF>),<sup>31</sup> and parcellated each hemisphere into

regions of interest according to the Neuromorphometric atlas.<sup>32</sup> GIF uses an atlas propagation and label fusion strategy to calculate the voxel probabilities of GM, white matter, and CSF<sup>31</sup>; this method has been previously used in MS and other neurodegenerative disorders.<sup>33,34</sup> The template library had 95 MRI brain scans (HCs and patients with AD) with neuroanatomic labels (<http://www.neuromorphometrics.com/>). This atlas, which is similar to the Mindboggle atlas, was developed to improve the consistency and clarity of the Desikan-Killiany protocol.<sup>32</sup>

To calculate brain masks and exclude segmentation errors outside of the brain, we used STEPS (Similarity and Truth Estimation for Propagated Segmentations, <http://cmictig.cs.ucl.ac.uk/niftyweb/program.php?p=BRAIN-STEPS>) based on a template library of 682 hand-drawn brain masks.<sup>35,36</sup> These maps were applied to each time point separately.

**REGIONAL VOLUME CALCULATION.** We visually assessed the segmentations to assure the quality for statistical analysis. To calculate regional volumes, we summed the probability of the segmented tissue voxels (GM or white matter) in each parcellated region and multiplied the sum with the voxel volume. We averaged values between left and right hemispheres. Next, we summarised the regional volumes according to Neuromorphometrics protocol by summing the volume of GM regions in the temporal, parietal, occipital, frontal lobes, cerebellum, and deep GM (DGM; thalamus, putamen, globus pallidus, caudate, and amygdala). We also obtained the volume of the brainstem and of the cerebral white matter.

Figure 1 shows the image analysis pipeline.

### Statistical Analysis

**BRAIN VOLUMES AT BASELINE AND RATES OF VOLUME CHANGES OVER TIME.** To investigate baseline volumes (intercept) and rates (slopes) of volume change by subject group and region, we used linear mixed-effects models with the volume at a given time as the response variable, and time and interactions with time as fixed-effect covariates.<sup>37</sup> This model estimates adjusted rate

TABLE . Baseline Characteristics of Participants

Group	Healthy Controls	CIS	RRMS	SPMS	PPMS
Total no. (no. of females)	203 (112)	253 (171)	708 (473)	128 (75)	125 (55)
Average follow-up in years (range)	1.83 (0.5–7.8)	1.46 (0.5–13.0)	2.72 (0–13)	2.06 (0.0–5.5)	2.85 (0.5–6.0)
Average age ( $\pm$ SD)	38.7 $\pm$ 10.5	33 $\pm$ 8	38.2 $\pm$ 9.8	48.2 $\pm$ 9.8	48.5 $\pm$ 10.1
Average disease duration ( $\pm$ SD)	—	0.4 $\pm$ 1.4	6.7 $\pm$ 7.3	15.6 $\pm$ 9.9	6.8 $\pm$ 5.9
Median EDSS (range)	—	1 (0.0–4.5)	2 (0–7)	6 (2.5–9.0)	5 (2–8)
Median T2 lesion load (ml) (first–third quartiles)	—	2.97 (1.01–5.04)	5.05 (2.05–11.79)	11.04 (3.18–23.14)	9.38 (2.69–22.02)
% (no.) of patients on DMTs	—	20 (52)	49 (345)	41 (52)	6 (8)

SD = standard deviation; CIS = clinically isolated syndrome; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary-progressive multiple sclerosis; PPMS = primary-progressive multiple sclerosis; ml = milliliter; EDSS = expanded-disability status scale; DMTs = disease modifying treatments.

while allowing for nested correlation structures, such as time of visit within subject within scanner, by incorporating, in this example, subject and scanner random intercepts, and a random slope on time. The interaction terms with time (eg, subject group  $\times$  time) allows the estimation of rate differences across the interacting variable, in this example subject groups or clinical phenotypes. Including another interaction with time, such as sex  $\times$  time, adjusts the rate for gender. In addition to time, the fixed-effect covariates were: scanner magnetic field, subject group, sex, age at baseline, and total intracranial volume (sum of the volumes of GM, WM, and CSF) at baseline; and the interactions of each of these with time. Disease duration was too highly correlated with age at baseline to give reliable estimation and was omitted from the final models. To estimate the percentage changes per unit (year) increase in time, we log-transformed the volume.<sup>38</sup> We adjusted time to zero for those visits in which a patient converted from one phenotype to another (eg, CIS to RRMS). We performed post-hoc analyses to identify specific GM regions within the cerebral lobes and among the DGM nuclei that showed significant differences between MS phenotypes, as well as the default-mode network regions.<sup>39</sup>


To investigate whether there is an association between the rate of loss in specific regions and MS phenotypes, three-way interactions were used, for example, clinical phenotype  $\times$  region  $\times$  time. We used R (version 3.2.2; R Foundation for Statistical Computing, Vienna, Austria) and the NLME package.<sup>40,41</sup>

For each model, we visually checked the heteroscedasticity (which is the unequal variance of a variable across the range of values of a second variable that predicts it) per group by plotting residuals against the fitted values.

We corrected for multiple comparisons accounting for the number of all the tests performed with the false-discovery rate (FDR) method.

**EFFECT OF MRI PROTOCOLS ON IMAGING MEASURES.** To assess the effect of the MRI protocol on MRI measures (we took into account the protocols rather than the centers because some centers acquired more than one protocol with more than one scanner), we included it as a fixed-effect variable in a separate mixed-effect model, and calculated the average effect sizes for MRI protocols and MS phenotypes (ie, disease effects) while fixing other variables.

**ASSESSING ASSOCIATIONS BETWEEN BRAIN TISSUE VOLUMES AND DISABILITY ACCRUAL.** For easier interpretation of clinical and imaging measures, we standardized volumes by subtracting the mean and dividing by the standard deviation (SD; Z-score). We analyzed CIS and relapse-onset patients together, because some patients had converted from CIS to RRMS, or from RRMS to SPMS. This allowed us to take advantage of a longer follow-up period. With similar mixed-effects models, we investigated the following three questions: (1) Are the baseline volumes of the DGM, the temporal, frontal, parietal, occipital and cerebellar GM, brainstem, and white matter, and white matter lesion load associated with EDSS at baseline?; (2) Are changes in all these regional volumes and white matter lesion load associated with EDSS changes over time?; and (3) Do baseline volumes of all these regions and white matter lesion at baseline predict time-to-EDSS progression (event = EDSS progression) during follow-up? The EDSS-progression event was defined as a 1.5 increase in EDSS, if the baseline EDSS was 0; 1-point increase if EDSS was less than or equal to 6; and 0.5 increase if EDSS was more than 6.<sup>42</sup> We used a Cox regression model to explore whether baseline volumes of these structures predicted time to event. We performed a post-hoc analysis using all GM regions to determine the most important predictors



**FIGURE 2:** Baseline volumes and annual percentage loss of brain regions in clinical phenotypes and healthy controls. Adjusted baseline values for HCs, CIS, RRMS, SPMS, and PPMS are shown in (A), where the adjusted mean is shown as a point, and error bars show the 95% confidence interval. Adjusted *p* values of pair-wise comparisons between groups are shown in Supplementary Table 4. Longitudinal analyses are shown in (B) and (C). Bar charts of the adjusted annual percentage of loss are shown in (B) for the predefined regions. Height of each bar chart is the average estimate of the percentage annual loss from the mixed-effects model for each group. Error bars represent 95% confidence interval of these estimates. Adjusted *p* values for pair-wise comparison between regions across clinical phenotypes and HCs are shown in Supplementary Table 4. White matter volumes are not shown in (B) and (C) because they did not show a significant change over time in any clinical phenotype. Post-hoc analyses of annual percentage loss are shown in (C) where DGM nuclei, temporal, limbic, and default mode network regions were selected. Similar to (B), the adjusted average annual percentage volume loss for these regions is the height of each bar chart and error bars represent 95% confidence intervals. Baseline values (A) and rates (B and C) were adjusted in a single mixed-effects hierarchical model including age, sex, total intracranial volume at baseline, scanner magnetic field, and their interactions with time as the fixed effects. Center, subject and visits were nested (hierarchical) random effects. HC = healthy controls; CIS = clinically isolated syndrome; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary-progressive multiple sclerosis; PPMS = primary-progressive multiple sclerosis. [Color figure can be viewed at [www.annalsofneurology.org](http://www.annalsofneurology.org)]

of time-to-EDSS progression (as defined above) and confirm that the results of the DGM were not affected by the bias of merging a higher number of cortical regions into the main lobes. We performed FDR correction to adjust for multiple comparisons.

**ADDITIONAL ANALYSES: SOFTWARE RELIABILITY AND EFFECTS OF DISEASE-MODIFYING TREATMENTS.** We carried out additional analyses to assess the reliability of brain volumes estimated with GIF software, FSL-FIRST, and SPM12, and effects of treatments on atrophy measures. We also performed area under the curve (AUC) analysis to examine the prognostic accuracy of adjusted DGM volumes at individual level (see Supplementary Material).

## Results

MRI scans of 1,417 subjects were analyzed (scans of 3 subjects were excluded because of significant motion artefacts on visual inspection and 4 because of registration issues because of missing MRI header information); 1,214 patients (253 had CIS, 708 had RRMS, 128 had SPMS, and 125 had PPMS), and 203 were HCs. In total, we analyzed 3,604 T1-weighted MRIs. Average number of scans per subject was 2.54 (SD = 1.04), with an average follow-up of 2.41 years (SD = 1.97) for patients and 1.83 (SD = 1.77) years for HCs (see the Table for follow-up information per group). The total numbers of participants with three or more visits for each group were: 90 HCs, 48 CIS, 334 RRMS, 39 SPMS, and 58 PPMS. A total of 96 patients with CIS (38%) converted to RRMS, and 28 patients with RRMS (4%) converted to SPMS during the follow-up.

There was a significant difference in sex ratio between groups ( $p < 0.001$ ; see the Table for sex ratios). Patients with progressive MS (SPMS and PPMS) had significantly greater disability than patients with RRMS and CIS (Mann-Whitney  $U$  tests,  $p < 0.001$ ; see the Table) and were older than RRMS ( $p < 0.001$ ; average difference = 10.7 years), CIS ( $p < 0.01$ ; average difference = 15.6 years), and HCs ( $p < 0.01$ , average difference = 10 years). Age was similar between patients with RRMS and HCs. Patients with CIS were younger than HCs ( $p < 0.01$ ; average difference = 4.9 years). Patients with CIS had the lowest T2 lesion load, and patients with SPMS had the highest T2 lesion load. Approximately half of patients with RRMS were on disease-modifying treatments (see the Table).

### **Brain Atrophy at Baseline in MS and Rates of Volume Changes Over Time**

At baseline, all clinical phenotypes (CIS, RRMS, SPMS, and PPMS) had significantly smaller cortical GM and DGM volumes than HCs. SPMS showed the lowest cortical GM and DGM volumes, followed by PPMS,

RRMS, and CIS. All clinical phenotypes, but not CIS, had significantly reduced whole brain and white matter volumes when compared to HCs (see Fig 2A).

The fastest regional decline in tissue volume over time was observed in the DGM in all clinical phenotypes (PPMS:  $-1.66\%$  per year; SPMS:  $-1.45\%$ ; RRMS:  $-1.34\%$ ; CIS:  $-0.88\%$ ;  $p < 0.01$ ) and in HCs ( $-0.94\%$ ). Rate of atrophy in the DGM was greater in RRMS, SPMS, and PPMS than CIS and HCs (all  $p$  values  $< 0.01$ ; (Fig 2B; Supplementary Tables 3 and 4), but did not differ between RRMS, SPMS, and PPMS. Rate of volume loss in the DGM in all MS patients together was significantly higher than that in the cortical and cerebellar GM and brainstem (although the rate of volume loss over time in these areas was still significant; all  $p$  values  $< 0.05$ ).

Volume loss of the whole cortical GM was faster in SPMS ( $-1.11\%$  per year), PPMS ( $-0.79\%$ ), RRMS ( $-0.67\%$ ), than HCs ( $-0.34\%$ ; all  $p$  values  $< 0.05$ ). Among the cortical regions, the temporal lobe GM showed a faster volume loss in SPMS ( $-1.21\%$ ) than RRMS ( $-0.77\%$ ) and CIS ( $-0.75\%$ ; all  $p$  values  $< 0.05$ ; Fig 2B; Supplementary Tables 3 and 4). Similarly, the parietal GM showed a faster volume loss in SPMS ( $-1.24\%$ ) than CIS ( $-0.63\%$ ;  $p < 0.05$ ; Fig 2B; Supplementary Tables 3 and 4). No differences in rates of volume loss were observed in the frontal and occipital GM between clinical phenotypes. Overall, all the cortical GM regions, with the exception of the occipital cortex, showed a faster rate of atrophy in MS than HCs (Fig 2B; Supplementary Table 4).

The white matter did not show a significant rate of volume loss in HCs or any of the clinical phenotypes.

There was no heteroscedasticity in the plots of residuals against fitted values.


In the post-hoc analyses, when looking at regions and clinical phenotypes, we found, that among the DGM nuclei, the putamen showed the fastest volume loss in PPMS ( $-2.6\%$ ). Within the temporal lobe GM, the fastest volume loss was observed in the temporal pole ( $-1.47\%$ ) and posterior insula in SPMS ( $-1.19\%$ ). When looking at the parietal lobe GM, the precuneus showed the fastest atrophy rates in SPMS ( $-1.28\%$ ; Fig 2C). Whereas the fastest rate of atrophy was observed in the DGM in SPMS, the temporal lobe GM showed the highest difference between SPMS and HCs (see Fig 2C).

There was no significant effect of sex on rates of atrophy. There was no significant association between GM volumes and T2 (or FLAIR) lesion load.

### **Regions Showing the Highest Rate of Loss**

When we compared the rate of volume loss across different regions in all patients (CIS, RRMS, SPMS, and

(A) **Baseline** DGM volume, but not baseline lobar cortical grey matter or whole brain volumes, can predict **future** EDSS progression. Predictive value of DGM volume is independent of clinical phenotypes.



**FIGURE 3: DGM volume predicts future progression of EDSS.** Survival curves for time to event (sustained EDSS progression; see Patients and Methods for definition) in CIS, relapse onset, and PPMS. We have analyzed CIS and relapse-onset patients together because a proportion of patients convert from CIS to RRMS, or from RRMS to SPMS, during the course of study. Hazard ratios for models with continuous outcome variables (regional volumes) are reported. DGM = deep gray matter; EDSS = Expanded-Disability Status Scale; HC, healthy controls; CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; PPMS, primary-progressive multiple sclerosis; HR = hazard ratio; CI = confidence interval. [Color figure can be viewed at [www.annalsofneurology.org](http://www.annalsofneurology.org)]

PPMS) together, the fastest decline (or lowest slope) was observed in the DGM (Supplementary Tables 3 and 4). Rate of loss in the cortical GM regions was similar between lobes and to that of the cerebellum. The slowest rate of loss was observed in the brainstem.

### Spatiotemporal Pattern of GM Volume Loss in Clinical Phenotypes

Although SPMS showed the lowest baseline volumes of cortical GM and DGM, and the rate of the DGM volume loss was faster in SPMS, PPMS, and RRMS than CIS and HCs, there was no significant association between rate of loss in specific regions and clinical phenotypes, which suggests that all clinical phenotypes share a similar spatiotemporal pattern of GM loss.

### Effect of MRI Protocols on Imaging Measures


The average effects of MS phenotypes on brain volumes at baseline were higher than the protocol effect on the brain volumes (protocol effects: whole brain = 4.3%; cortical GM = 5.1%; DGM = 8.5%; disease effects: whole brain = 4.8%; cortical GM = 5.2%; DGM = 13.7%). Average effects of MS phenotypes were higher

than the effects of protocol on the rates of atrophy of the cortical GM and DGM (protocol effects: cortical GM = 0.14%; DGM = 0.21%; disease effects: cortical GM = 0.57%; DGM = 0.53%), but not those of the whole brain (protocol effect = 0.51%; disease effect = 0.38%).

### Association Between EDSS and GM Loss

In all clinical phenotypes combined, lower DGM and cortical GM volumes at baseline were associated with higher disability, as measured by the EDSS (DGM  $\beta = -0.71$ ,  $p < 0.0001$ ; cortical GM  $\beta = -0.22$ ;  $p < 0.0001$ ). Under the assumption of a linear relationship between EDSS and GM volume, this suggests that for every Z-score decrease in the DGM and cortical volume at baseline, the baseline EDSS increased on average by 0.7 and 0.22, respectively.

There was a significant progression of EDSS in both relapse-onset and PPMS patients, which on average increased by 0.07 and 0.2 per year, respectively. When we examined associations between the rate of EDSS changes and rate of changes in the volumes of cortical GM regions, cerebellar GM, and DGM over time, only the rate of loss in the DGM was associated with



**FIGURE 4:** Risk of EDSS progression during follow-up for each Z-score volume loss of the brain regions at baseline (post-hoc analysis). Results of the post-hoc Cox proportional hazards univariate models are shown for the time-to-event analyses (event = sustained EDSS worsening; see Patients and Methods for the definition) in the regions of Neuromorphometrics' atlas, which are shown in (A). The predictors were the baseline volumes of the regions shown in the x-axes of (B) for CIS, RRMS, and SPMS and (C) for PPMS. CIS, RRMS, and SPMS were analyzed together because several patients convert from one phenotype to another. Brain maps are shown in the left column, and bar charts of the same analyses are shown in the right column of (B) and (C). Only regions whose *p* value of the survival analysis survived FDR correction (adjusted *p* < 0.05) are shown in (B) and (C). The y-axes show the risk of progression for each Z-score loss in the volume of the corresponding brain region on x-axes. For example, for every Z-score loss of the thalamus volume at baseline, the risk of EDSS worsening during follow-up increased by 37% for the CIS, RRMS, and SPMS group and 40% for PPMS. Color maps code the importance of baseline volumes of the regions to predict EDSS worsening (or EDSS progression) during follow-up. The absolute values of coefficients for ventricular volumes are shown in (B), because they have an effect in the opposite direction of other structures. Error bars indicate the 95% confidence intervals. EDSS = Expanded-Disability Status Scale; HC, healthy controls; CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; PPMS, primary-progressive multiple sclerosis. [Color figure can be viewed at [www.annalsofneurology.org](http://www.annalsofneurology.org)]

disability accumulation ( $\beta = -0.04$ ; 95% confidence interval [CI],  $-0.02, -0.06$ ;  $p = 0.006$ ). Under the assumption of a linear relationship between EDSS and rate of GM volume loss over time, this suggests that every SD (*Z*-score) loss in the rate of DGM volume corresponded to an annual EDSS gain of 0.04.

The percentage of patients who had EDSS progression during follow-up (or who experienced the “event”) was 26%. When we looked at baseline predictors of disability accumulation, without any longitudinal imaging measure in the model, only the DGM predicted future

EDSS progression. The hazard ratio (95% CI, *p* value) for time-to-EDSS progression was 0.73 (95% CI, 0.65, 0.82;  $p < 0.0001$ ), which suggests that, for every SD (*Z*-score) decrease in the DGM volume at baseline, the risk of presenting a shorter time to EDSS worsening during the follow-up increased by 27% (95% CI, 18–35). The hazard ratio remained similar when we analyzed relapse-onset and PPMS patients separately (0.72 and 0.73, respectively). Figure 3 illustrates the survival curve for these analyses.

In the post-hoc analyses, baseline thalamic volume had the highest predictive value of EDSS progression

during follow-up in both PPMS and the relapse-onset groups, by increasing the risk to a shorter time to EDSS worsening of 37% in relapse-onset MS and 40% in PPMS (Fig 4B,C). In this analysis, the predictive value of the thalamus was followed by that of the hippocampus and angular gyrus in relapse-onset MS (Fig 4B), and by that of the putamen, posterior insula, and temporal pole in PPMS (Fig 4C).

There were no significant differences in rates of loss in patients who were receiving disease-modifying drugs and those who were not (see Supplementary Text). Analyses with GIF software, FSL-FIRST, and SPM12 confirmed the reliability of brain volumes estimates (see details in Supplementary Text). AUC analysis showed that DGM volumes were similar to a random classifier in prognosticating individual patients (see details in Supplementary Text).

## Discussion

In this large, multicenter study, we have shown that volume loss in DGM over time was faster than that observed in other brain regions across all clinical phenotypes, and DGM volume loss was the only GM region associated with disability accumulation. Additionally, we found that the smaller DGM volume at baseline was associated with increased risk of shorter time to EDSS progression, in agreement with previous studies that showed smaller DGM volume associated with higher disability.<sup>14,15</sup> Interestingly, we found that atrophy rates of the GM of cortical lobes were the fastest in SPMS, and were faster in the temporal lobe in SPMS in comparison with RRMS and CIS and in the parietal lobe in SPMS in comparison to CIS. However, no significant association between cortical regions and disability progression was detected. Overall, our findings suggest that the development of DGM atrophy may drive disability accumulation irrespective of clinical phenotypes, thereby becoming a useful outcome measure in neuroprotective clinical trials. Although the spatiotemporal pattern of atrophy remains similar across MS phenotypes, some cortical regions show accelerated atrophy in SPMS than RRMS and/or CIS. We now discuss these results in turn and in detail.

The pathological events that underpin DGM atrophy are not known, but this is generally interpreted as the result of neurodegeneration. Previous studies have shown that DGM atrophy is more severe in patients with progressive MS, longer disease duration, and worse cognitive performance.<sup>14,15,43</sup> Our post-hoc analyses showed that the thalamus, which is the DGM's largest component, was a better predictor of future disability than other regions, and the rate of atrophy in the putamen was the highest across DGM nuclei. Previous studies, including those using

advanced MRI, have found that thalamic damage at study entry was associated with higher disability.<sup>13–15</sup> DGM structures are extensively connected with cortical GM regions, and therefore DGM atrophy could be attributed to retrograde and anterograde neurodegeneration through tracts that connect GM areas. For example, the extent of cellular density loss in the thalamus is associated with neurodegeneration in the remote (but connected) cortical regions, over and beyond the extent of atrophy explained by demyelination in connecting tracts.<sup>44</sup> There is also evidence of other neurodegenerative mechanisms in the DGM nuclei. For example, their higher load of iron than other regions can accumulate oxidised lipids, which are associated with neurodegeneration.<sup>45</sup> In our healthy controls, rate of DGM atrophy was faster than that in other regions, suggesting that it may be a hotspot for both age- and disease-related atrophy in the human brain, although a methodological issue, related to its more uniform structure than other brain regions, cannot be excluded. In AUC analysis, we found that, at the individual level, DGM volume lacks prognostic value, which is attributed to the high variability typical of volumetric MRI studies.<sup>46</sup> Nevertheless, the DGM volume holds strong promise as a marker of disease progression (at the group level) with the potential to respond to neuroprotective treatments that target neurodegeneration in MS.

Interestingly, the temporal lobe showed a significant acceleration in SPMS when compared to both RRMS and CIS. Similarly, the parietal lobe GM showed a significant acceleration of atrophy in SPMS in comparison to CIS. Our post-hoc analysis showed that the temporal pole and insula were the most affected structures in the temporal GM. Pathological studies have demonstrated an increase in the rate of neurodegeneration, especially in the temporal regions, during progressive stages of MS in comparison to RRMS and CIS.<sup>47,48</sup> Overall, a global pathological process in MS<sup>49</sup> may become more pronounced in certain regions, such as the temporal GM, because of other mechanisms, such as static exposure to CSF (the insula in the temporal lobe) or hypoxia in watershed areas (some DGM nuclei such as the pallidum). For example, meningeal inflammation and cortical demyelination, which may play a role in cortical atrophy, preferentially affect deep sulci, such as the insula, where there is more exposure to static inflammatory cytokines.<sup>2</sup> Our findings also suggest that regions with more connections may be vulnerable to atrophy. For example, among the parietal cortical regions, the precuneus, a core part of an important functional brain network (default mode network), showed the fastest atrophy rates in SPMS.<sup>39</sup> Thus, acceleration of atrophy during SPMS may be explained by cortical network collapse

with advancing of degeneration from initial injury sites (focal lesions in the white matter or initial DGM degeneration) to interconnected neocortical systems.<sup>50</sup> We found that MS phenotypes shared a common spatiotemporal pattern of volume loss (no significant three-way interaction of time  $\times$  region  $\times$  phenotype). This shows, in line with previous studies, that the difference in pathology of progressive MS is only quantitative rather than qualitative in comparison to RRMS.<sup>2,51</sup>

Cortical GM atrophy was observed at study entry across clinical phenotypes, even in CIS, when compared to HCs, and was the greatest in progressive MS, in agreement with earlier studies.<sup>17,52</sup> Our findings of faster whole brain atrophy in SPMS, PPMS, and RRMS than CIS, who, in turn, showed higher cortical atrophy than HCs, are similar to previous studies on longitudinal whole brain atrophy,<sup>5,53,54</sup> regional atrophy,<sup>17,55–57</sup> and pathology of MS phenotypes.<sup>2,47</sup> Our study confirms our previous findings that relationships between whole brain atrophy and clinical changes are weak or absent<sup>5</sup> and shows DGM atrophy as a stronger marker of clinical disability. Although the GM volumes of cortical lobes could not predict future EDSS progression, the more detailed post-hoc analyses showed that regional volumes, such those of the hippocampus and the angular gyrus, were associated with future EDSS progression. These regions are highly connected to other regions, and especially the angular gyrus (like the precuneus) acts as a hub in the default mode network, which could make it vulnerable to atrophy, as explained above.<sup>39</sup>

This study was not designed to assess the effect of treatment on atrophy rates, but does study atrophy while adjusting for possible confounding effects. The rates of atrophy in all clinical phenotypes were similar in people who were receiving disease-modifying treatments to those who were not. Even though we could not ascertain the duration of treatments attributed to retrospective nature of this study, the majority (90%) of patients on disease-modifying treatments were receiving first-line injectable drugs (interferon or glatiramer acetate) before study entry. The effects of these drugs on brain atrophy are modest at best.<sup>58,59</sup> Therefore, drug effects are unlikely to be confounders of our analysis.

One strength of our study is that we included a large number of patients, who underwent the same protocol on the same MRI scanner over time at single sites. However, different MRI protocols could have an effect on atrophy measures and is a limitation of our study.<sup>60,61</sup> We therefore used a hierarchical statistical design based on scanner. Our study was powerful enough because the effects of clinical phenotype on the regional rates of atrophy were higher than the effects of between-center variation.

We chose GIF software to segment and parcellate the brain<sup>31</sup> because it allowed inclusion of two-dimensional MRI data (which we had for one center), and did not require any manual editing, unlike Freesurfer, which would have been unfeasible for such large number of scans. Our reliability analysis showed excellent agreement between GIF-derived DGM volume and that obtained using FSL-FIRST, and between GIF-derived cortical volumes and those obtained using SPM12, respectively. Therefore, we chose to present the results obtained with GIF because it allowed us to rely on only one method to segment DGM and cortical GM, and estimate total intracranial volume (TIV). We used TIV to adjust for variations in head size, rather than the skull size, so that a more reliable estimate of head size was obtained, irrespectively of the field of view, the choice of the inferior cutoff of the brain for the analysis, and demographic factors (eg, age, weight).<sup>62</sup> With regard to the statistical methods, we used mixed-effects models to calculate atrophy rates,<sup>41</sup> which naturally accommodated multiple (three or more) time points with varying intervals between follow-ups, and patients who convert from one phenotype to another (eg, CIS to RRMS). These two issues are cumbersome to address with methods that rely on pairwise comparisons (eg, SIENA, BSI) and suffer from higher variance in brain atrophy estimates as the interval between two scans increases.<sup>63,64</sup> Mixed-effects modeling, instead, estimates a variance component to eliminate implausible inconsistencies.<sup>65,66</sup> Based on our experience and the results of this study, we recommend the acquisition of high-resolution 3D-T1 images (isotropic 1mm<sup>3</sup>). Several methods can calculate DGM volumes, such as FSL-FIRST and GIF. We recommend the use of the GIF software when it is desirable to use the same method to segment both the cortex and DGM.

There were also limitations in this study. The majority of centers did not provide MRI scans of HCs; however, we included a large number of HCs including those from an external initiative (PPMI). Our findings of volume changes in HCs were consistent with the literature. Meta-analyses have shown, in individuals aged <70 years, rate of whole brain loss ranges from 0 to  $-0.5$  (our study =  $-0.04$ ), GM loss ranges from 0% to  $-0.5\%$  per year (cortical GM in our study =  $-0.34\%$ ),<sup>67</sup> and the subcortical structures may show loss of up to  $-1.12\%$  (DGM in our study =  $-0.94$ ).<sup>68</sup> Cognitive functions were not tested, and it is unknown whether cortical patterns of GM atrophy over time were associated with cognitive impairment. Clinical trials in MS (and in progressive MS in particular) include confirmed disability progression, based on the EDSS, as a primary outcome measure. Although for EDSS the model-estimated

coefficients and their  $p$  values and confidence intervals are valid for comparison between brain regions, the absolute value of these coefficients must be interpreted with caution, because the EDSS does not have a uniform linear interpretation. Because this was a retrospective study, the duration of treatments before entry to the study could not be ascertained for all participants. Disease-modifying drugs may have lasting effects; for example, they may slow the accrual of disability after a decade.<sup>59,69</sup> Moreover, MRI sequences sensitive to cortical lesions were not available, and the effects of cortical lesions on atrophy measures remain unknown.

In conclusion, DGM atrophy showed the most rapid development over time—extending previous cross-sectional studies that showed a relationship between DGM atrophy and disability—was most closely associated with disability accumulation and predicted the time to EDSS worsening. In phase II trials of neuroprotective medications in MS, DGM atrophy measures may therefore have greater potential to show treatment effects than other regional GM or whole brain measures. There was a disconnect between DGM atrophy and cortical atrophy rates. Temporal and parietal cortices showed a faster rate of atrophy in SPMS than RRMS and/or CIS, whereas DGM showed a faster rate of atrophy in SPMS than CIS only, suggesting that neurodegeneration in GM regions may proceed at a different rate which should be taken into account in the design of clinical trials.

## Acknowledgment

A. Eshaghi has received an ECTRIMS-MAGNIMS Fellowship (<http://www.magnims.eu>) and MSIF McDonald Fellowship (<http://www.msif.org>). The authors acknowledge The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at University College London Hospitals (UCLH) for their support. C. Tur has received an ECTRIMS post-doctoral research fellowship in 2015. D. Alexander has received funding for this work from EPSRC (M020533, M006093, and J020990) as well as the European Union's Horizon 2020 research and innovation programme under grant agreement nos. 634541 and 666992. PPMI (<http://www.ppmi-info.org>)—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners (see <http://www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors/> for the full list).

## Author Contributions

A.E., D.C.A., O.C., A.J.T., F.B., F.P., M.J.C., D.C., D.R.A., C.A.M.G.W.-K., and C.T. contributed to the conception and design of the study. A.E., O.C., W.B., C.T.,

F.D.A., S.H.P., N.C., N.D.S., M.L.S., M.B., S.R., C.G., M.F., M.A.R., A.R., J.S.G., H.V., C.E.L., J.K., L.P., C.E., F.P., S.O., C.A.M.G.W.-K., D.C., and C.E. contributed to the acquisition and analysis of data. A.E. and O.C. contributed to drafting the text and preparing the figures.

## Potential Conflicts of Interest

Nothing to report.

## References

1. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. *Neurology* 2014;83:1022–1024.
2. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. *Lancet Neurol* 2015;14:183–193.
3. Geurts JGG, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. *Lancet Neurol* 2012;11:1082–1092.
4. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. *Lancet Neurol* 2006;5:158–170.
5. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. *Neurology* 2010;74:1868–1876.
6. De Stefano N, Stromillo ML, Giorgio A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2016;87:93–99.
7. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. *Lancet* 2014;383:2213–2221.
8. Chataway J. MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial - ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/study/NCT01910259?term=ms-smart&rank=1>.
9. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. *Ann Neurol* 2008;64:255–265.
10. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. *Brain J Neurol* 2008;131(pt 3):808–817.
11. Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. *Mult Scler J* 2011;17:1098–1106.
12. Steenwijk MD, Geurts JJ, Daams M, et al. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. *Brain J Neurol* 2016;139(pt 1):115–126.
13. Eshaghi A, Bodini B, Ridgway GR, et al. Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. *Neuroimage* 2014;86:257–264.
14. Rocca MA, Mesaros S, Pagani E, et al. Thalamic damage and long-term progression of disability in multiple sclerosis. *Radiology* 2010;257:463–469.
15. Schoonheim MM, Hulst HE, Brandt RB, et al. Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. *Neurology* 2015;84:776–783.
16. Henneman WJP, Sluiter JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. *Neurology* 2009;72:999–1007.
17. Ceccarelli A, Rocca MA, Pagani E, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. *Neuroimage* 2008;42:315–322.

18. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011;69:292–302.
19. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology* 2014; 83:278–286.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983;33:1444–1452.
21. Tustison NJ, Avants BB, Cook PA, et al. N4ITK: improved N3 bias correction. *IEEE Trans Med Imaging* 2010;29:1310–1320.
22. Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. *Neuroimage* 2012;59:3774–3783.
23. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. *Med Image Anal* 2001;5:143–156.
24. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. *IEEE Trans Med Imaging* 2001;20:45–57.
25. Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. *Hum Brain Mapp* 2012;33:2062–2071.
26. Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2013;84:1082–1091.
27. Amato MP, Hakiki B, Goretti B, et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. *Neurology* 2012;78:309–314.
28. Reuter M, Fischl B. Avoiding asymmetry-induced bias in longitudinal image processing. *Neuroimage* 2011;57:19–21.
29. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. *Neuroimage* 2010;53:1181–1196.
30. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. *Neuroimage* 2012;61:1402–1418.
31. Cardoso MJ, Modat M, Wolz R, et al. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. *IEEE Trans Med Imaging* 2015;34:1976–1988.
32. Klein A, Tourville J. 101 labeled brain images and a consistent human cortical labeling protocol. *Front Neurosci* 2012;6:171.
33. Pardini M, Sudre CH, Prados F, et al. Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2016;87:1212–1217.
34. Bocchetta M, Cardoso MJ, Cash DM, et al. Patterns of regional cerebellar atrophy in genetic frontotemporal dementia. *Neuroimage Clin* 2016;11:287–290.
35. Prados F, Cardoso MJ, Leung KK, et al. Measuring brain atrophy with a generalized formulation of the boundary shift integral. *Neurobiol Aging* 2015;36(suppl 1):S81–S90.
36. Jorge Cardoso M, Leung K, Modat M, et al. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcellation. *Med Image Anal* 2013;17:671–684.
37. Bernal-Rusiel JL, Greve DN, Reuter M, et al. Statistical analysis of longitudinal neuroimage data with linear mixed effects models. *Neuroimage* 2013;66:249–260.
38. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. *Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models* [Internet]. Springer New York; 2006. <https://www.google.co.uk/search?tbo=p&tbnm=bks&q=isbn:1461413532>.
39. Zhang D, Raichle ME. Disease and the brain's dark energy. *Nat Rev Neurol* 2010;6:15–28.
40. R Core Team. *R: A Language and Environment for Statistical Computing* [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2014. <http://www.R-project.org/>.
41. Pinheiro JC, Bates D. *Mixed-Effects Models in S and S-PLUS* [Internet]. Springer; 2009. <https://books.google.co.uk/books?isbn=1441903178>.
42. Healy BC, Engler D, Glanz B, et al. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. *Mult Scler Int* 2013;2013:189624.
43. Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. *Neuroimage* 2012;59:331–339.
44. Kolasinski J, Stagg CJ, Chance SA, et al. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. *Brain J Neurol* 2012;135(pt 10):2938–2951.
45. Hametner S, Wimmer I, Haider L, et al. Iron and neurodegeneration in the multiple sclerosis brain. *Ann Neurol* 2013;74:848–861.
46. Barkhof F. Brain atrophy measurements should be used to guide therapy monitoring in MS - NO. *Mult Scler* 2016;22:1524–1526.
47. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. *Brain J Neurol* 2011;134(pt 9):2755–2771.
48. Haider L, Zrzavy T, Hametner S, et al. The topography of demyelination and neurodegeneration in the multiple sclerosis brain. *Brain J Neurol* 2016;139(pt 3):807–815.
49. Lindberg RL, De Groot CJ, Certa U, et al. Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. *J Neuroimmunol* 2004;152:154–167.
50. Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. *Neuron* 2009;62:42–52.
51. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. *Brain J Neurol* 2005;128(pt 11):2705–2712.
52. Audoin B, Zaaraoui W, Reuter F, et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2010;81:690–695.
53. Kalkers NF, Ameziame N, Bot JC, et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. *Arch Neurol* 2002;59:1572–1576.
54. Lukas C, Minneboo A, de Groot V, et al. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2010;81:1351–1356.
55. Riccitelli G, Rocca MA, Pagani E, et al. Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. *Hum Brain Mapp* 2011; 32:1535–1543.
56. Mallik S, Muhlert N, Samson RS, et al. Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: a voxel-based analysis study. *Mult Scler* 2015;21:423–432.
57. Lansley J, Mataix-Cols D, Grau M, et al. Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. *Neurosci Biobehav Rev* 2013;37:819–830.
58. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet* 2004;364:1489–1496.
59. Kappos L, Edan G, Freedman MS, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. *Neurology* 2016;87:978–987.

60. Biberacher V, Schmidt P, Keshavan A, et al. Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. *Neuroimage* 2016;142:188–197.
61. Bendfeldt K, Hofstetter L, Kuster P, et al. Longitudinal gray matter changes in multiple sclerosis—differential scanner and overall disease-related effects. *Hum Brain Mapp* 2012;33:1225–1245.
62. Malone IB, Leung KK, Clegg S, et al. Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. *Neuroimage* 2015;104:366–372.
63. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. *Neuroimage* 2002;17:479–489.
64. Smith SM, Rao A, De Stefano N, et al. Longitudinal and cross-sectional analysis of atrophy in Alzheimer’s disease: cross-validation of BSI, SIENA and SIENAX. *Neuroimage* 2007;36:1200–1206.
65. Cash DM, Frost C, Iheme LO, et al. Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. *Neuroimage* 2015;123:149–164.
66. Frost C, Kenward MG, Fox NC. The analysis of repeated “direct” measures of change illustrated with an application in longitudinal imaging. *Stat Med* 2004;23:3275–3286.
67. Hedman AM, van Haren NE, Schnack HG, et al. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. *Hum Brain Mapp* 2012;33:1987–2002.
68. Fraser MA, Shaw ME, Cherbuin N. A systematic review and meta-analysis of longitudinal hippocampal atrophy in healthy human ageing. *Neuroimage* 2015;112:364–374.
69. University of California, San Francisco MS-EPIC Team., Cree BAC, Gourraud PA, et al. Long-term evolution of multiple sclerosis disability in the treatment era. *Ann Neurol* 2016;80:499–510.